首页> 外文期刊>中国神经再生研究(英文版) >Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases:a case report of improvement in relapsing auto-immune optic neuropathy
【24h】

Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases:a case report of improvement in relapsing auto-immune optic neuropathy

机译:视网膜和视神经疾病的干细胞眼科治疗研究(SCOTS):复发性自身免疫性视神经病变改善的一例报告

获取原文
获取原文并翻译 | 示例
       

摘要

We present the results from a patient with relapsing optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board ap-proved clinical trial and has become the largest ophthalmology stem cell study registered at the National Institutes of Health to date (www.clinicaltrials.gov Identiifer NCT 01920867). SCOTS utilizes autologous bone marrow-derived stem cells (BMSCs) for treatment of retinal and optic nerve diseases. Pre-treatment and post-treatment comprehensive eye exams of a 54 year old female patient were performed both at the Florida Study Center, USA and at The Eye Center of Columbus, USA. As a consequence of a relapsing optic neuritis, the patient’s previously normal visual acuity decreased to between 20/350 and 20/400 in the right eye and to 20/70 in the left eye. Signiifcant visual ifeld loss developed bilaterally. The patient underwent a right eye vitrectomy with injection of BMSCs into the optic nerve of the right eyeand retrobulbar, subtenon and in-travitreal injection of BMSCs in the left eye. At 15 months after SCOTS treatment, the patient’s visual acuity had improved to 20/150 in the right eye and 20/20 in the left eye. Bilateral visual fields improved markedly. Both macular thickness and fast retinal nerve fiber layer thickness were maximally improved at 3 and 6 months after SCOTS treatment. The patient also reduced her mycophenylate dose from 1,500 mg per day to 500 mg per day and required no steroid pulse therapy during the 15-month follow up.
机译:我们介绍了干细胞眼科治疗研究(SCOTS)中治疗的复发性视神经病变患者的结果。 SCOTS是经过机构审查委员会批准的临床试验,并已成为迄今为止在美国国立卫生研究院注册的最大的眼科干细胞研究(www.clinicaltrials.gov Identiifer NCT 01920867)。 SCOTS利用自体骨髓干细胞(BMSC)来治疗视网膜和视神经疾病。在美国佛罗里达研究中心和美国哥伦布眼科中心对一名54岁女性患者进行了治疗前和治疗后的全面眼科检查。由于视神经炎复发,患者以前的正常视力在右眼下降到20/350至20/400,在左眼下降到20/70。明显的双侧视力减退。该患者接受了右眼玻璃体切除术,向右眼的视神经中注射了BMSC,然后向左眼球后,筋膜和玻璃体内注射了BMSC。 SCOTS治疗后15个月,右眼患者的视力提高到20/150,左眼患者的视力提高到20/20。双边视野明显改善。 SCOTS治疗后3和6个月,黄斑厚度和视网膜神经纤维快速层厚度均得到最大改善。该患者还将她的麦考酚酯剂量从每天1,500 mg减少到每天500 mg,并且在15个月的随访期间不需要类固醇脉冲疗法。

著录项

  • 来源
    《中国神经再生研究(英文版)》 |2015年第9期|1507-1515|共9页
  • 作者单位

    Retina Associates of South Florida, Margate, FL, USA;

    MD Stem Cells, Ridgeifeld, CT, USA;

    Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD, USA;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:44:33
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号